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355 ABSTRACT  
56 Dietary nitrate ( ) ingestion appears to enhance exercise capacity and performance in  3
57 young individuals whereas inconclusive findings have been reported in older people. We 
58 conducted a double-blind, cross-over randomized clinical trial in older normal weight and 
59 overweight healthy participants testing whether beetroot juice (a rich source of ) for one  3
60 week may increase nitric oxide bioavailability via the non-enzymatic pathway and enhance 1) 
61 exercise capacity during an incremental exercise test, 2) physical capability and 3) free-living 
62 physical activity.  
63 Twenty non-smoking healthy participants aged 60-75y and BMI 20.0-29.9kg/m2 were 
64 included. Pre and post supplementation resting, sub-maximal, maximal and recovery gas 
65 exchanges were measured. Physical capability was measured by hand-grip strength (HGS), 
66 time-up-and-go (TUG), repeated-chair-rising-test (RCRT), and 10m walking speed (WLS). 
67 Free-living physical activity was assessed by triaxal accelerometry. Changes in urinary and 
68 plasma concentrations were measured by gas chromatography mass spectrometry.  3   
69 Nineteen participants (M/F=9/10) completed the study. Beetroot juice increased significantly   
70 both plasma and urinary concentrations (p<0.001) compared to placebo. Beetroot juice  3   
71 did not influence resting, sub-maximal and maximal oxygen consumption during the 
72 incremental exercise test. In addition, measures of physical capability and physical activity 
73 levels measured in free-living conditions were not modified by beetroot juice ingestion. 
74 The positive effects of beetroot juice ingestion on exercise performance seen in young 
75 individuals were not replicated in healthy, older adults. Whether aging represents a modifier 
76 of the effects of dietary on muscular performance is not known and mechanistic studies  3   
77 and larger trials are needed to test this hypothesis.
78
79 Keywords: inorganic nitrate, nitric oxide, exercise, oxygen consumption, aging 
480 1. INTRODUCTION
81 Aging is characterized by a progressive decline in muscle mass and strength which are risk 
82 factors for physical disability[1]. Aging is also associated with modifications of 
83 mitochondrial bioenergetics with consequent effects on muscular performance[2]. Dietary 
84 nitrate  supplementation enhances muscular efficiency in humans[3, 4], a finding  3 )
85 which can be explained by increased nitric oxide (NO) bioavailability and the role of NO in 
86 modulating mitochondrial coupling and bioenergetics of muscular activity[5, 6]. However, 
87 the majority of  supplementation studies have been conducted in healthy, physically  3
88 active young adults[7, 8] and few studies have evaluated the effects of dietary  on  3
89 physical or muscular function in older people[9-11]. Larsen et al in 2007[12] was the first to 
90 report reduced sub-maximal O2 uptake in young healthy adults after three-day oral 
91 supplementation with potassium . Kenjale et al[10] observed delayed onset of  3
92 claudication after three days of oral  supplementation in older patients with peripheral  3
93 arterial disease (PAD). However, subsequent studies reported contrasting results for the 
94 effects of dietary on exercise performance in healthy older people[9, 13] as well as in at  3  
95 risk populations (i.e., those with diabetes[11], heart failure[14], and chronic obstructive 
96 pulmonary disease (COPD)[15, 16]). All studies employed a double-blind randomized cross-
97 over study design and administered beetroot juice to increase  intake. However,  3
98 differences in study duration,  dose or assessment of exercise capability likely   3
99 contributed to the observed heterogeneous responses. For example, outcomes have included 
100 sub-maximal [12, 15, 17] or maximal oxygen (O2) uptake [18-20] assessed with incremental 
101 standardised tests [12, 15, 21] as well as time trials [22-24] or physical capability tests [9, 
102 25], all of which were performed in controlled settings. No study has investigated the effects 
103 of dietary supplementation on free living physical activity.  3  
5104 We hypothesized that dietary  supplementation would increase NO bioavailability,  3
105 muscular energetics and exercise performance  with significant changes expected in sub-
106 maximal, maximal and recovery O2 uptake  which may translate into beneficial effects on 
107 physical capability and free living physical activity. To test these hypotheses, we conducted a 
108 double-blind, cross-over, placebo controlled RCT in older healthy adults to investigate the 
109 effects of beetroot juice, chosen as a rich source of dietary , on physical activity  3
110 outcomes measured in research (O2 uptake during incremental cycle ergometer exercise, 
111 walking speed, time-up-and-go, repeated chair rising test and hand grip strength) and free 
112 living (accelerometry) settings. 
113 2. METHODS and MATERIALS
114 The trial was approved by the North of Scotland Research Ethics committee (14/NS/0061) 
115 and conducted in accordance with the Declaration of Helsinki. Written informed consent was 
116 obtained from all participants. The study was a double-blind, cross-over, placebo-controlled 
117 RCT which took place between May and August 2014 across two sites (Newcastle upon Tyne 
118 and Sheffield). The duration of the each intervention was one week with a wash-out period 
119 between treatments of at least one week. This trial was registered in the International 
120 Standard Randomized Controlled Trial Number Register (ISRCTN19064955). 
121 2.1 Participants: Twenty male and female, older (60-75 y) non-obese adults (BMI range: 
122 18.5 - 29.9 kg/m2) were enrolled in the study. Participants were non-smokers and weight 
123 stable. Participants were included in the study if they did not have medical conditions or were 
124 not taking medications that might influence the study outcomes. A full list of the inclusion 
125 and exclusion criteria is provided in the Online Supplementary Material. Participants were 
126 asked to maintain their habitual diet and to avoid using chewing gum or mouth wash for at 
127 least 48 prior to the baseline visits (first and third visit) and during each of the one-week 
128 supplementation periods. 
6129 2.2 Randomization: A randomization list for each site was generated by a member of staff not 
130 involved in the study using www.sealedenvelopes.com. Each participant was randomized to 
131 the cross-over interventions (i.e., placebo   or   placebo). Intervention agents  3  3
132 were dispensed at each baseline visit by two members of staff not involved in the study who 
133 had access to the stored beetroot juice and ensured the correct treatment allocation. 
134 2.3 Study Overview: A telephone screening was performed to check eligibility according to 
135 the trial inclusion and exclusion criteria. Eligible participants were invited for a further 
136 screening visit at the research facilities including measurement of BMI, resting BP and 
137 resting 12-lead electrocardiography (ECG). Participants were asked to arrive after a 12-hour 
138 overnight fast and having avoided strenuous physical activity for three days preceding the 
139 visit. If eligible, participants were randomized to a cross-over intervention and the baseline 
140 assessment continued with the measurement of body composition, collection of blood and 
141 urine samples and assessment of physical capability. Participants then rested for one hour and 
142 consumed a meal providing approximately 300kcal (CHO=85%, PRO=3%, FAT=12%). In 
143 addition, during this one-hour rest period, participants completed a series of questionnaires to 
144 assess dietary intake and physical activity. After the one-hour rest, participants were 
145 explained the exercise test while they accustomized to the ergometer. The exercise protocol is 
146 described in Figure S1 of the Online Supplementary Material. After the exercise test, 
147 instructions were provided for self-administration of the nutritional intervention (14 bottles of 
148 either  -rich or  -depleted beetroot juice; 70ml x 2/day; Beet It, James White Ltd,  3  3
149 UK) and asked to consume one bottle of beetroot juice each morning and evening for the 
150 subsequent 7 days. The daily dose of  -rich (intervention) or  -depleted (placebo)  3  3
151 beetroot juice contained ~12mmol and ~0.003mmol of , respectively. Participants were  3
152 provided with instructions and forms for recording wearing time of the accelerometer. This 
153 concluded Visit 1 of the trial. Participants returned to the research facilities in the morning of 
7154 day eight after they had completed a seven-day supplementation period. A detailed medical 
155 interview was conducted to ascertain any side effects experienced during the supplementation 
156 period. A resting 12-lead ECG was performed and, if normal, the study visit was completed 
157 by repeating the same assessments as performed during Visit 1. At the end of the second visit, 
158 participants were asked to resume their habitual diet and physical activity. After a wash out 
159 period of at least seven days the second phase (including Visits 3 and 4) was conducted 
160 similar to the first phase with the exception that participants crossed-over experimental arms 
161 i.e. consumed the other intervention agent. 
162 2.4 Body Composition: Bioelectrical impedance analyses (BIA) (Newcastle: TANITA 
163 418MA, Tanita Ltd, Japan; Sheffield: InBody 720 Analyser, InBody Bldg, Korea) was used 
164 to assess fat mass (FM) and fat free mass (FFM). Body weight, height and waist 
165 circumference (WC) were measured using standardized protocols. 
166 2.5 Resting Blood Pressure: Resting BP was measured in triplicate using an automated BP 
167 monitor (Omron M3, Omron Healthcare, UK) with the participant seated comfortably for 15 
168 min prior to measurement and the arm supported at the level of the heart. The recorded value 
169 was calculated as the mean of the three measurements.
170 2.6 Physical Capability: A battery of tests (hand grip strength (HGS), timed up and go 
171 (TUG), repeated chair rise test (RCRT) and 10m walking speed (WLS)), performed in the 
172 same order at each visit, was completed at baseline and at the end visit of each phase. 
173 Triplicate measurements of HGS were performed in both arms at baseline and after 
174 intervention using a digital dynamometer (Takei 5401, Takei, Japan). The average of six 
175 measurements was calculated. To complete the TUG, participants were asked to stand up 
176 from a chair, walk three meters at a self-selected comfortable speed, cross a line on the floor, 
177 turn around, walk back, and sit down again. The RCRT was completed using a standard chair 
178 without armrests. Participants had both arms crossed against the chest, starting from the 
8179 seated position and standing up (legs straight) and sitting down (full weight on the chair) and 
180 the test calculates the time required (in seconds) to complete five repeated chair stands. For 
181 the WLS, a 10-m path with a flying start was used to avoid acceleration/deceleration effects 
182 associated with starting and stopping during this assessment. The middle 6-m of this path 
183 were used for the measurement. Patients were instructed to walk as fast as they can and the 
184 time (in seconds) to complete the 6-m path was recorded.
185 2.7 Objective Measurement of Free Living Physical Activity: Participants were asked to wear 
186 a triaxial accelerometer (GT3X ActiGraph accelerometer (Pensacola, FL, USA)) above the 
187 right hip for eight consecutive days during waking hours and to remove it only for water 
188 activities (for example, swimming or bathing). Accelerometery data were collected in one-
189 minute epochs. Non-wear time was defined as 60 min or more of consecutive zero counts. 
190 One participant experienced a device malfunction and data were excluded from subsequent 
191 analysis. Counts per minute were converted into minutes of sedentary time (less than or equal 
192 to 100 counts per min), light (100-759 counts per min), moderate (19525724 counts per 
193 min) and vigorous-intensity (5725+ counts per min) physical activity[26]. Physical activity 
194 energy expenditure was calculated using the Freedson approach[26].  
195 2.8 Dietary and Lifestyle Questionnaires: The 9-item short form of the International Physical 
196 Activity Questionnaire (IPAQ) was used to record duration of four intensity levels of 
197 physical activity: 1) vigorous-intensity activity, 2) moderate-intensity activity, 3) walking, 
198 and 4) sitting. A combined total physical activity score was calculated and expressed in 
199 MET-minutes/week[27]. The EPIC Food Frequency Questionnaire (FFQ) was administered 
200 at baseline and the FETA software used to extract dietary (energy and nutrient) 
201 information[28]. 
202 2.9 Exercise Test: An incremental exercise test was performed at baseline and at the end of 
203 each intervention period to assess pulmonary gas exchange variables at rest, during sub-
9204 maximal and maximal intensities and in the post-exercise recovery phase. Briefly, each 
205 participant underwent cardiopulmonary exercise testing on an electronically-braked cycle 
206 ergometer. The protocol included a five-minute resting phase followed by a 20 watts stepwise 
207 increase in workload every three minutes while they were invited to maintain a stable 
208 pedalling rate (60-70 rpm). After reaching 80 watts, participants were asked to exercise until 
209 exhaustion (ramp protocol: 10 watts/minute), which was followed by a five-minute passive 
210 recovery period. A graphical description of the protocol is described in Figure S1 of the 
211 Online Supplementary Material. Pulmonary gas exchange and ventilation were measured 
212 (Newcastle: MetaMax 3B, Cortex Biophysik, Leipzig, Germany; Ultima CardiO2, 
213 Medgraphics, St Paul, MN, USA). Heart rate (HR) was measured during all tests using 
214 cardio-thoracic impedance. Oxygen uptake ( O2), minute ventilation ( E), carbon dioxide V V
215 excretion rate ( CO2), and respiratory exchange ratio (RER) were assessed. O2 assessed V V
216 during the last minute of the incremental exercise test was recorded as O2peak. Ventilatory V
217 threshold was calculated using the V-slope method[29]. 
218 2.10 Blood and Urine Collection: Fasting blood samples were collected at the beginning of 
219 each visit and centrifuged at 3,000rpm for 10 min at 4 °C within 30min of collection. 
220 Aliquots of plasma and serum were frozen and stored at 80 °C for subsequent analyses. 
221 Mid-stream urine samples were collected, in fasting conditions, into sterile containers and 
222 stored at 20 °C for subsequent analyses.
223 2.11 Biomarker Analysis: A modified version of the gas chromatography mass spectrometry 
224 (GC-MS) method proposed by Tsikas et al[30] was used to determine   concentrations in  3
225 urine and plasma samples. The protocol and validation of the modified GC-MS method have 
226 been described elsewhere[31]. This method showed good repeatability, with coefficients of 
227 variation for replicate analyses of 7.8%, 8.6% and 12.0% for saliva, urine and plasma 
228 samples, respectively. 
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229 2.12 Sample size: The primary outcome of the study was the effect of  supplementation  3
230 on VO2 consumption during sub-maximal exercise. Data on the expected effect size were 
231 obtained from a previous cross-over design study testing the effects of incremental exercise 
232 on sub-maximal and maximal O2 consumption in young adults after a six-day nitrate 
233 supplementation[32] which showed that O2 during moderate exercise was 1.53±0.12 L·min-1 V
234 and 1.45±0.12 L·min-1 in the placebo and nitrate groups respectively. On this basis, 20 
235 participants were needed in a cross-over randomized trial to detect a difference of 0.08±0.12 
236 L·min-1 with a power of 0.80 and alpha of 0.05.
237 2.13 Statistical Analyses: Repeated-Measures General Linear Models (GLM) were used to 
238 test the effect at the end of each intervention of  supplementation on measures of  3
239 exercise performance and physical capability. Treatment (  vs placebo) was entered as a  3
240 group factor (Tr) and the time points of the incremental exercise test as the repeated factor 
241 (Ti). Post-hoc comparison between treatment groups at each time point was performed using 
242 the Fisher LSD test. The area under the curve (AUC) for O2 consumption during the V
243 incremental exercise test was calculated at baseline and end of study using the trapezoidal 
244 method. A paired t test was used to compare differences between the two interventions for the 
245 AUCs and free living physical activity outcomes. Data were presented as means ± SD or 
246 means ± 95% confidence intervals (95%CI). Analyses were conducted using Statistica 10 for 
247 Windows (StatSoft.Inc, Tulsa, OK, USA). Statistical significance was set at <0.05.        
248 3. RESULTS
249 3.1 Participants characteristics, safety and Compliance with Interventions: Twenty 
250 participants were randomized to the intervention. One person developed an ischemic event 
251 during the physical exercise testing performed at the second visit and he was excluded from 
252 the study (Figure 1). The remaining 19 participants (mean age 64.7±3.0 years (range: 60 - 75 
253 years)) reported no side effects apart for the expected urine discoloration related to the 
11
254 excretion of beetroot juice pigment (beeturia). All participants reported that they consumed 
255 all the intervention drinks provided and all of them completed all the measurements included 
256 in the study protocol. This included high compliance with wearing of the accelerometer (total 
257 wear time: ~7.5-8.0 days out of maximum 8 days).
258 3.2 Dietary Intake and Self-Reported Physical Activity: Energy intake was 2728±1430 
259 kcal/day with 47±8%, 35±7% and 18±4% of energy provided by carbohydrates, fats and 
260 protein respectively. Self-reported physical activity was again not different between the 
261 placebo and the  arms as participants in both groups reported an average increase in total  3
262 physical activity of approximately 300 METs/week (p=0.99) (Table 1 and Table S2 of the 
263 Online Supplementary Material).
264 3.3 Body Composition: Mean baseline BMI was 25.6±3.4 kg/m2 with 12 participants being in 
265 the overweight category :V@I6/8H*2). Body weight was stable across the study with 
266 changes of 0.01±0.85 kg in the placebo and -0.16±0.57 kg in the intervention group (p=0.51). 
267 Similarly, no statistically significant between-treatment differences were found for FFM 
268 (0.02±1.00 kg vs 0.11±0.77 kg, p=0.65) and FM (-0.03±0.79 kg vs 0.27±0.75 kg, p=0.86) 
269 (Table 1 and Table S2 of the Online Supplementary Material).
270 3.4 Resting Blood Pressure: Baseline resting systolic and diastolic BP ranged from 100.0 to 
271 168.0 mmHg and 62.0 to 97.0 mmHg, respectively. The decrease in systolic BP (-5.05±9.45 
272 mmHg) with  supplementation was approximately double that observed with the placebo  3
273 (-2.64±9.04 mmHg) but this difference was not significant (p=0.48). Both interventions 
274 produced similar falls in diastolic BP (-3.70±5.59 vs -3.49±6.42 mmHg, p=0.90) (Table 1 
275 and Table S2 of the Online Supplementary Material).
276 3.5 Laboratory biomarkers: Concentrations of nitrite plus nitrate + , NOx) in  2  3
277 plasma and urine increased substantially after  supplementation by 150±77% and  3
278 979±488% but not after the placebo intervention (-9±33% and -13±34%, respectively). 
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279 3.6 Gas-Exchange during Standardized Exercise: Nitrate supplementation had no significant 
280 effect on pulmonary gas exchange (O2 and CO2) measured during resting, sub-maximal, 
281 maximal and recovery phases of the incremental exercise test. O2 consumption increased 
282 linearly with the intensity of the workload and O2 consumption at exhaustion was 1.67±0.51 
283 and 1.64±0.55 L·min-1 following and placebo interventions (p=0.86), respectively. There  3
284 was a steady and comparable decline in O2 consumption during the 5-minute recovery phase 
285 with return to baseline resting values for both interventions (Figure 3A). The AUCs for O2 
286 consumption for both treatments were similar (p=0.89, data not showed). Similarly, weight-
287 adjusted O2 consumption did not significantly different between the  and placebo groups  3
288 (p=0.99, Figure S2 of the Online Supplementary Material). O2 consumption at ventilatory 
289 threshold was similar for the  (0.90±0.39 L·min-1) and placebo (0.91±0.39 L*min-1)  3
290 treatments (p=0.35) and no differences between the two interventions were observed for CO2 
291 production, RER, E and HR (Figure 3B to 3E). Time to exhaustion was shorter following V
292 the  intervention but the difference was not significant (p=0.10, Figure 3F). The  3
293 adjustment of the analyses for baseline values of gas exchanges did not modify the results 
294 (data not showed). A summary of the data for each time point is provided in Table S3 of the 
295 Online Supplementary Material.
296 3.7 Physical Capability and Objective Assessment of Free Living Physical Activity: Physical 
297 performance was assessed using a battery of tests measuring strength, performance and 
298 balance. supplementation produced small improvements in performance for all tests but  3
299 the effects were not statistically significant (Table 2). Similarly,  supplementation had  3
300 no significant effect on total energy physical activity or on each type of physical activity (i.e., 
301 sedentary, light, moderate, vigorous) (Table 3).  
302 4. DISCUSSION
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303 4.1 Summary of Research Findings: This is the first study to evaluate the effects of dietary 
304   supplementation on physical performance assessed in research settings and free-living  3
305 conditions in healthy older participants. Contrary to the large body of evidence supporting a 
306 positive effect of dietary   supplementation on exercise performance, our study showed  3
307 no effects of   supplementation on O2 consumption during sub-maximal and maximal  3
308 exercise performance in older healthy participants. In addition, there were no significant 
309 effects of dietary   supplementation on measures of physical capability and free-living  3
310 physical activity. 
311 4.2 Comparison with Body of Evidence: Research into the effects of dietary on exercise  3
312 performance has been influenced by two significant events: 1) first paper published by Larsen 
313 et al in 2007[12] reporting a reduced sub-maximal O2 consumption after three-day oral   3
314 supplementation and 2) development of a -depleted and -enriched concentrated  3  3
315 beetroot juice which has allowed the design of robust double-blind, randomized nutritional 
316 interventions[11]. Since 2007, several RCTs have tested the effects of dietary on  3
317 exercise performance in humans. A small number of these trials supplemented participants 
318 with pharmacological preparation (sodium or potassium )[3, 12, 19, 21, 33-35] whereas  3
319 the majority of the trials used beetroot juice as a way to increase dietary  intake[9-11, 16,  3
320 23, 25, 36]. Most of the studies recruited mainly young, physically fit participants and only a 
321 few trials [9-11, 13, 15-17, 37, 38] have tested the effects of dietary in older participants  3
322 (mean age range: 63  70 years). The first study in older participants was conducted in eight 
323 patients with PAD who received 3.5 hours before the exercise testing either 500ml of 
324 beetroot juice or orange juice[10]. The study found an increased exercise time before onset of 
325 claudication pain and time to exhaustion. The remaining studies in older participants have 
326 reported contrasting results, which may be explained by differences in the duration of 
14
327 supplementation (range: 2.5 hours[15] to 14 days[11]), type of population (healthy[9, 13], 
328 PAD[11], COPD[15, 16], type 2 diabetes[11], heart failure[14, 17]), dose of  (range: ~  3
329 300  ~ 700mg) or exercise test (walking test[9, 10, 16, 25], incremental exercise[10, 14], 
330 forearm exercise[13]). Overall, the results have showed a reduced responsiveness of older 
331 participants to dietary supplementation. Negative results were seen in healthy older  3
332 participants[9] and patients with diabetes[25] and COPD[16], whereas improved exercise 
333 performance was observed in patients with heart failure[14] and PAD[10]. Our study 
334 confirmed that dietary  supplementation for one week in older adults produced no    3
335 beneficial effects on physical capability or exercise performance measured in standardized 
336 clinical settings. In addition, we reported for the first time a lack of effect of      3
337 supplementation on free living physical activity, which may entail a re-examination of the 
338 usefulness of dietary  supplementation as a viable nutritional population strategy to    3
339 enhance physical performance.
340 4.3 Biological Mechanisms: Dietary is converted to NO in a two-step reduction process  3
341 proceeding via the intermediate formation of . The first step is performed by saprophytic  2
342 bacteria with reductase activity colonizing the dorsal area of the tongue.  is then either  2
343 converted to NO in the acidic gastric environment or transported in blood and reduced 
344 enzymatically in areas of tissues with lower oxygen tension and pH where metabolic 
345 demands are higher[39]. The latter conditions are frequently encountered in areas of 
346 contracting muscles, which favour the conversion into NO to enhance coupling between  2  
347 muscle perfusion and metabolic activities[5]. The improved metabolic activity reported in 
348 previous studies appears to be related to an increased mitochondrial efficiency and/or 
349 reduction of the energetic cost of muscle contractions[6]. This raises important questions 
350 about why  supplementation does not improve physical capability or function in older  3
15
351 people and stimulate future studies to investigate mechanisms that may explain the reduce 
352 effects of   supplementation on muscular performance with aging. Putative mechanisms    3
353 may involve altered reductase capacity to convert  into NO or reduced effects of NO on    3
354 skeletal muscle mediated by age-related changes in mitochondrial function and contractile 
355 efficiency. Whether higher doses or longer supplementation periods may overcome the 
356 alleged age-related decline in muscular response to dietary  supplementation is currently    3
357 not known. 
358 4.4 Limitations: The small sample size and the relatively short duration of the intervention 
359 are important limitations of this study and therefore the results may require a careful 
360 interpretation. While we measured plasma concentrations using GCMS, due to logistic  2  
361 constraints it was not possible to process the samples immediately after collection to 
362 minimise degradation. These results are therefore unavailable. However, previous  2  
363 studies involving dietary supplementation in older participants where plasma  3   2  
364 concentration was measured, an increase in plasma concentrations similar to the amount   3  
365 observed in this study occurred alongside a (8$W 	$3 rise in plasma concentrations  2  
366 [40].
367 5. CONCLUSIONS
368 We tested for the first time the ergogenic effects of dietary supplementation in older  3
369 participants on exercise performance and free-living physical activity and found that, overall, 
370 dietary supplementation had no effects. The results seem to indicate that aging may  3
371 modify the muscular response to dietary supplementation. However, these results await  3
372 confirmation in future studies with larger samples size and in targeted populations with 
373 impaired muscular performance. 
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522 FIGURE LEGENDS
523 Figure 1: Description of recruitment phases
524 Figure 2: Changes in plasma and urinary nitrate after either one-week supplementation of 
525 nitrate-rich or nitrate-depleted beetroot juice in 19 older healthy adults. Data presented as 
526 means±95%CI. A paired t test was applied to test differences between the two interventions 
527 at baseline and end of the study.
528 Figure 3: Differences in gas exchanges and heart rate after one-week supplementation with 
529 either nitrate-rich or nitrate-depleted (placebo) beetroot juice in 19 older healthy adults. Data 
530 presented as means±95%CI.  A repeated-measure ANOVA model was applied to test 
531 differences between the two interventions at the end of each intervention.  O2 = oxygen V
532 volume; CO2 = carbon dioxide volume; RER= respiratory exchange ratio; E= pulmonary V V
533 ventilation; HR= heart rate. 
534
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Table 1: Baseline characteristics (N=19)
Means SD
M/F 9/10
Age (years) 64.7 3.0
BMI (kg/m2) 25.6 3.4
WC (cm) 88.5 13.9
FM (kg) 22.0 6.3
FFM( kg) 50.2 11.5
Resting Systolic BP (mmHg) 127.4 16.1
Resting Diastolic BP (mmHg) 76.2 9.6
Energy Intake (Kcal/day) 2728 1431
CHO (g/day) 308 152
FAT (g/day) 107 73
PRO (g/day) 103 57
Saturated Fat (g/day) 35.6 26.5
Unsaturated Fat (g/day) 14.1 10.4
Fibre (g/day) 23.9 13.0
535 N= number of participants; M= Male; F= Female; Body mass index= body mass index; WC= waist circumference; FM= fat 
536 mass; FFM= fat free mass; BP= blood pressure; CHO= carbohydrate; FAT= fat; PRO= protein; 
22
537
538      
Table 2: Measures of physical capability before and after supplementation with either nitrate-rich or nitrate-depleted 
(placebo) beetroot juice for one week.
Placebo Nitrate
Baseline End Baseline End Main 
Effect
Hand-Grip Strength (kg) 28.92±9.09 29.49±9.26 29.24±9.34 29.51±9.92 0.53
Time Up and Go (seconds) 5.44±0.76 5.62±0.76 5.67±1.07 5.58±1.00 0.53
Repeated Chair Standing (seconds) 8.03±2.24 7.65±1.73 7.73±1.77 7.60±1.73 0.41
10m Walking Test (seconds) 2.83±0.60 2.80±0.44 2.94±0.53 2.84±0.54 0.79
539 Data presented as means±SD. A repeated-measure ANOVA model was applied to test differences between the two interventions at the end of 
540 each intervention in 19 older healthy adults.  
541
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Table 3: Measures of free living physical activity after supplementation with either nitrate-rich or nitrate-depleted (placebo) beetroot juice measured over each one-week intervention with either placebo or nitrate.
Placebo Nitrate @ P
Total Physical Activity (kcal) 3378.66±1615.62 3066.11±1274.17 -312.55 ± 904.17 0.14
Average Length of Sedentary Bouts (minutes) 170.15±41.57 175.73±68.76 5.57±68.73 0.72
Daily Average of Sedentary Bouts (minutes) 184.10 ± 194.84 136.10 ± 155.60 -48.01 ± 85.25 0.40
Average Length of Sedentary Breaks (minutes) 110.31±42.81 129.10±86.42 18.78±100.36 0.42
Daily Average of Sedentary Breaks (minutes) 331.05 ± 102.62 322.68 ± 94.62 -8.38 ± 56.28 0.79
Time in Sedentary Activity (minutes) 8993.68±984.47 8473.15±2139.85 -520.52±1782.42 0.21
Time in Light Activity (minutes) 2690.31±1194.68 2520.63±1171.47 -169.68±806.39 0.37
Time in Moderate Activity (minutes) 249.42±149.13 222.42±144.92 -26.94±97.83 0.24
Time in Vigorous Activity (minutes) 32.94±94.86 20.52±56.40 -12.42±54.82 0.19
543 Data presented as means±SD. ]A difference between placebo and beetroot juice groups. A paired t test was used to compare differences between the two interventions for free living physical activity outcomes in 19 
544 older healthy adults. 
545
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Figure S1:  Study design (upper panel) and protocol of standardised exercise test (lower 
panel). After an initial screening participants were randomised to either placebo or nitrate-
rich beetroot juice in cross-over fashion for one week. After a one-week wash out period, 
participants were invited to return to the research centre and crossed to the other intervention. 
Measurements were conducted at baseline and end of each intervention giving a total of four 
measurement sessions. Detailed measurements of physical performance were performed at 
the research centre while when at home physical activity was monitored by triaxial 
accelerometer. Blood and urine samples were collected at each visit for the measurement of 
various biomarkers. A standardised exercise test was performed at each visit using a cyclo-
ergometer and continuous monitoring of gas exchanges.  The test started with a 5-minute rest 
following by a stepwise increase in workload by 20 watts very three minutes until reaching a 
workload of 80 watts. After this value participants were invited to exercise exhaustion 
(ramping 10 watts per minute) which was then followed by a 5-minute recovery period. 
VMAX = peak of gas exchanges.
Table S1: List of inclusion and exclusion criteria applied in the recruitment of participants willing to enrol in the 
trial. 
Inclusion criteria
We aim to recruit 20 male and female, older (60-75 y) non-obese subjects (BMI Range: 18.5 - 29.9 kg/m2). 
Subjects will be non-smokers and weight stable.
Exclusion criteria are (reason for exclusion)
 Current participation in other research clinical studies
 Very high resting blood pressure readings ( 	
 and/or Diastolic 		>
 Vegetarianism (likely to have very high nitrate intake)
 High physical activity level (	 steps per day; may have BMI in overweight range but low fat 
mass)
 Weight change more than 3.0kg in the last 2 months (important influence on systemic metabolism and 
vascular function).
 Active cancer and any diagnosis of malignant cancer in the last 5 years (systemic effects on study 
outcomes).
 Diagnosis of chronic and acute metabolic, cardiovascular and inflammatory conditions interfering with 
the study outcome (systemic effects on study outcomes). For example flu, Crohns Disease, rheumatoid 
arthritis, heart disease.
 Weight loss medications (sibutramine, orlistat, rimonabant) and history of bariatric surgery (weight loss 
related changes in systemic metabolism).
 Previous diagnosis of type 1 or type-2 diabetes treated with insulin and oral hypoglycaemic agents 
(modification of regulation of intermediate metabolism). Type 2 diabetic patients treated with diet only 
will be included in the study.
 Drugs: corticosteroids, sildenafil, aspirin, NSAIDs, diuretics, beta-blockers, antacids, anti-hypertensive 
(Ca++ channel blockers, ACE inhibitors), statins and any other anti-dyslipidaemic 
agent,anticoagulants, nitrate-derived agents, anti-cholinergic, (all drugs may have an effect on NO 
production via different mechanisms).
 Subjects on hormonal therapies (oestrogens, thyroxine, progesterone) and psychiatric drugs 
(antidepressants, sedatives, antipsychotics) will be excluded if dose has been started/changed in the 
previous three months (make sure that these disorders are under strict control to avoid interference 
with the study outcomes).
 Haematological disorders including self-reported anaemia, (risk for the participant and effects on the 
study outcomes).
 Major surgical operations interfering with the study outcomes (systemic effects on study outcomes). 
 Alcohol intake 	 units/week for men and 	 units/week women
 Blood donations in the previous 3 months.
Table S2: Changes in body composition, resting blood pressure (BP), self-reported physical activity and nitrate intake after one-week supplementation with either nitrate-rich or nitrate-
depleted (placebo) beetroot juice in 19 older healthy adults.
Placebo Beetroot
Baseline End % Baseline End % Pbetween %
Weight (kg) 72.31±14.26 72.29±14.22 0.01±0.85 72.3±14.20 72.4±14.23 -0.16±0.57 0.51
FFM (kg) 50.25±11.72 50.27±11.64 0.02±1.00 50.23±11.70 50.12±11.85 0.11±0.77 0.65
FM (kg) 22.05±6.16 22.01±6.04 -0.03±0.79 22.07±6.36 22.35±6.14 0.27±0.75 0.86
Resting Systolic BP 
(mmHg)
125.78±15.37 123.13±15.19 -2.64±9.04 129.09±17.17 124.04±15.47 -5.05±9.45 0.48
Resting Diastolic BP 
(mmHg)
75.93±10.07 72.44±8.67 -3.49±6.42 76.54±9.55 72.83±8.87 -3.70±5.59 0.90
IPAQ (METs/week)
Walking
Moderate
Vigorous
Total
1850.60±1719.84
674.73±2175.92
400.00±858.21
2925.34±2238.93
2136.31±1937.68
626.31±1515.81
468.63±1239.44
3231.26±2004.45
285.71±1548.69
48.42±713.46
68.63±833.11
305.92±1958.07
1596.15±1613.84
642.10±1334.29
168.42±457.35
2406.68±1762.43
1694.28±1791.14
829.47±1627.58
190.73±481.69
2714.50±1993.12
98.13±1371.98
187.36±1221.66
22.31±291.39
307.81±1590.87
0.66
0.49
0.38
0.99
Data presented as means±SD. C, difference between baseline and end of study. A paired t test was used to compare differences C between the two interventions. IPAQ= international 
physical activity questionnaire
Figure S2: Differences in oxygen consumption after one-week supplementation with either nitrate-rich or nitrate-depleted (placebo) beetroot 
juice in 19 older healthy adults. Data presented as means±95%CI.  A repeated-measure ANOVA model was applied to test differences between 
the two interventions in 19 older healthy adults.  VO2= oxygen volume adjusted for body weight;
Table S3: Changes in gas exchanges and heart rate after one-week supplementation with either nitrate-rich or nitrate-depleted (placebo) beetroot juice in 19 
healthy older adults.
Placebo Beetroot
Baseline End % Baseline End % P&%
O2 (L*min-1)V
Baseline
20W
40W
60W
80W
VMAX
Recovery  1min
Recovery  2min
Recovery  3min
Recovery  4min
Recovery  5min
0.26±0.07
0.64±0.12
0.81±0.13
1.01±0.15
1.21±0.20
1.61±0.58
1.10±0.41
0.64±0.25
0.48±0.17
0.37±0.14
0.33±0.12
0.27±0.06
0.62±0.10
0.80±0.11
1.00±0.15
1.21±0.20
1.63±0.55
1.08±0.29
0.67±0.22
0.51±0.18
0.36±0.09
0.32±0.10
-0.006±0.04
0.02±0.06
0.004±0.05
0.008±0.08
0.0009±0.11
-0.02±0.20
0.01±0.27
-0.02±0.15
-0.03±0.12
0.01±0.08
0.008±0.09
0.25±0.06
0.63±0.10
0.82±0.14
1.02±0.20
1.23±0.22
1.62±0.48
1.06±0.24
0.68±0.20
0.54±0.18
0.39±0.09
0.33±0.11
0.26±0.06
0.63±0.11
0.82±0.12
1.01±0.13
1.26±0.18
1.67±0.51
1.07±0.31
0.66±0.18
0.49±0.15
0.37±0.10
0.33±0.10
-0.006±0.02
0.007±0.07
0.007±0.07
0.003±0.10
-0.02±0.10
-0.05±0.14
-0.01±0.23
0.02±0.12
0.05±0.10
0.01±0.09
-0.004±0.06
0.99
0.55
0.88
0.86
0.37
0.69
0.74
0.26
0.06
0.85
0.64
O2 *BW-1 (mL*min-1*kg-1)V
Baseline
20W
40W
60W
80W
VMAX
Recovery  1min
Recovery  2min
Recovery  3min
Recovery  4min
Recovery  5min
3.70±0.75
8.95±0.97
11.38±1.06
14.21±1.26
17.06±2.07
21.99±5.20
14.98±3.83
8.81±2.50
6.51±1.75
5.06±1.15
4.72±1.09
3.83±0.60
8.79±0.75
11.40±1.34
14.15±1.50
17.09±2.60
22.43±4.82
15.08±2.60
9.40±2.45
7.00±2.02
4.98±0.74
4.46±0.96
-0.13±0.68
0.16±0.21
-0.02±0.22
0.06±0.30
-0.02±0.41
-0.43±0.62
-0.10±0.87
-0.58±0.56
-0.49±0.46
0.08±0.26
0.26±0.24
3.60±0.63
9.08±1.25
11.71±1.60
14.33±2.04
17.25±2.56
21.94±4.31
14.56±1.96
9.40±2.01
7.28±1.86
5.39±0.62
4.40±0.93
3.68±0.79
8.75±1.31
11.59±1.64
14.32±1.92
17.83±2.96
23.05±4.40
14.82±2.69
9.08±1.96
6.86±1.58
5.14±0.98
4.59±0.99
-0.07±0.52
0.33±1.14
0.12±1.11
0.01±1.79
-0.57±1.83
-1.10±2.38
-0.25±2.99
0.31±1.74
0.41±1.42
0.25±1.11
-0.18±0.94
0.73
0.64
0.66
0.91
0.28
0.49
0.89
0.17
0.15
0.64
0.22
CO2 (L*min-1)V
Baseline
20W
40W
60W
80W
VMAX
Recovery  1min
Recovery  2min
Recovery  3min
Recovery  4min
Recovery  5min
0.27±0.09
0.60±0.11
0.80±0.14
1.07±0.15
1.34±0.23
1.86±0.67
1.39±0.52
0.87±0.30
0.65±0.21
0.49±0.18
0.43±0.15
0.26±0.06
0.60±0.09
0.82±0.10
1.07±0.13
1.37±0.22
1.95±0.69
1.44±0.45
0.93±0.28
0.67±0.19
0.48±0.13
0.41±0.12
0.0008±0.05
-0.007±0.07
-0.01±0.09
-0.007±0.14
-0.02±0.20
-0.09±0.25
-0.04±0.29
-0.05±0.19
-0.02±0.14
0.10±0.10
0.01±0.11
0.25±0.07
0.60±0.12
0.82±0.17
1.07±0.22
1.41±0.26
1.86±0.58
1.40±0.33
0.90±0.22
0.65±0.19
0.49±0.11
0.42±0.12
0.26±0.07
0.61±0.14
0.83±0.16
1.09±0.15
1.41±0.20
1.98±0.55
1.40±0.40
0.90±0.24
0.65±0.18
0.49±0.14
0.42±0.13
-0.008±0.03
-0.007±0.08
-0.01±0.10
-0.01±0.15
-0.06±0.18
-0.11±0.16
-0.07±0.28
-0.005±0.13
0.02±0.10
0.005±0.09
-0.01±0.07
0.59
0.99
0.88
0.85
0.43
0.79
0.77
0.34
0.17
0.87
0.34
RER
Baseline
20W
40W
60W
80W
VMAX
Recovery  1min
Recovery  2min
Recovery  3min
Recovery  4min
Recovery  5min
0.97±0.17
0.93±0.10
0.99±0.09
1.06±0.11
1.10±0.11
1.16±0.09
1.26±0.08
1.38±0.15
1.36±0.18
1.31±0.12
1.22±0.12
0.98±0.12
0.97±0.11
1.02±0.10
1.08±0.11
1.13±0.11
1.19±0.09
1.31±0.11
1.40±0.18
1.35±0.16
1.33±0.10
1.25±0.09
-0.009±0.16
-0.03±0.09
-0.02±0.09
-0.01±0.11
-0.02±0.11
-0.03±0.09
-0.04±0.13
-0.02±0.14
0.005±0.19
-0.02±0.11
-0.03±0.10
0.96±0.11
0.95±0.12
0.99±0.13
1.05±0.12
1.09±0.13
1.15±0.11
1.25±0.12
1.35±0.19
1.30±0.21
1.28±0.16
1.22±0.14
0.96±0.13
0.97±0.15
1.01±0.13
1.07±0.14
1.13±0.14
1.20±0.12
1.30±0.07
1.37±0.11
1.33±0.10
1.31±0.10
1.25±0.13
0.005±0.11
-0.02±0.10
-0.02±0.08
-0.02±0.09
-0.03±0.09
-0.04±0.11
-0.05±0.11
-0.02±0.13
-0.03±0.15
-0.03±0.14
-0.02±0.14
0.74
0.58
0.86
0.80
0.63
0.67
0.94
0.94
0.55
0.85
0.90
VE (L*min-1)
Baseline
20W
40W
60W
80W
VMAX
Recovery  1min
Recovery  2min
Recovery  3min
Recovery  4min
Recovery  5min
9.34±2.69
17.13±3.58
21.58±4.27
28.08±5.87
35.98±10.39
51.95±20.27
38.63±14.79
25.43±7.47
19.39±5.73
16.15±5.78
14.46±5.61
12.94±18.99
16.63±3.06
21.49±3.86
27.86±6.72
36.72±12.98
54.99±21.88
39.64±11.79
26.84±6.75
20.41±5.40
15.73±5.51
13.76±5.48
-3.60±18.73
0.49±1.87
0.08±2.01
0.21±3.85
-0.74±6.16
-3.03±9.14
-1.00±11.92
-1.41±6.14
-1.01±5.18
0.42±3.79
0.70±4.58
8.10±1.64
17.13±3.58
22.06±4.91
28.39±7.49
36.44±11.55
52.48±20.55
36.84±10.58
26.12±5.68
20.40±5.42
16.01±4.39
14.09±4.89
8.25±1.84
16.72±3.70
21.63±5.13
27.93±6.27
37.10±11.03
56.31±23.57
38.93±13.40
26.17±8.03
20.20±5.82
16.34±5.45
14.09±5.21
-0.14±1.01
0.40±1.54
0.43±1.87
0.45±2.52
-0.66±3.61
-3.82±7.22
-2.08±9.85
-0.05±5.13
0.19±3.07
-0.33±3.38
-0.45±1.97
0.42
0.87
0.48
0.83
0.95
0.77
0.74
0.43
0.35
0.54
0.31
HR (bpm)
Baseline
20W
40W
60W
80W
VMAX
Recovery  1min
Recovery  2min
Recovery  3min
Recovery  4min
Recovery  5min
76.15±14.00
93.23±14.37
102.23±15.09
118.15±22.99
128.07±27.09
143.18±14.97
122.00±14.76
103.11±26.72
99.89±13.90
92.89±11.82
90.89±12.01
73.75±12.74
90.00±10.81
99.94±12.96
111.76±16.27
125.21±21.04
147.55±15.65
123.11±15.26
109.37±14.04
100.53±13.71
93.42±13.76
91.16±12.25
2.39±6.49
3.23±10.85
2.28±13.19
6.39±21.64
2.86±25.23
-4.36±20.00
-1.10±10.68
-6.26±25.51
-0.63±13.45
-0.52±9.36
-0.26±8.90
73.15±9.57
88.81±11.64
101.26±18.55
112.73±19.55
121.36±21.85
143.26±15.43
122.47±15.98
108.74±14.02
99.53±14.34
92.58±12.37
90.47±11.82
71.52±8.60
88.65±11.46
96.81±16.56
108.13±22.04
121.31±25.07
141.34±17.38
121.89±18.67
109.37±16.74
101.00±15.06
93.42±15.81
88.89±11.69
1.62±4.92
0.15±9.19
4.44±6.96
4.60±8.54
0.05±16.19
1.92±8.32
0.57±9.52
-0.63±10.63
-1.47±12.00
-0.84±10.63
1.57±4.97
0.72
0.41
0.44
0.75
0.69
0.29
0.60
0.38
0.84
0.92
0.53
O2 = oxygen volume; CO2 = carbon dioxide volume; RER= respiratory exchange ratio; VE= pulmonary ventilation; HR= heart rate. Data presented as V V
means±SD.  C, difference between baseline and end of study.  A paired t test was used to compare differences C between the two interventions
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CONSORT 2010 checklist of information to include
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Section/Topic Item 
No
Checklist item Reported on page 
No
Title and 
abstract
   
1a Identification as a randomised trial in the title  1
1b Structured summary of trial design, methods, 
results, and conclusions (for specific guidance see
CONSORT for abstracts)
 3
Introduction
Background 
and objectives
2a Scientific background and explanation of rationale  4
2b Specific objectives or hypotheses  5
Methods
Trial design 3a Description of trial design (such as parallel, 
factorial) including allocation ratio
 5-6
3b Important changes to methods after trial 
commencement (such as eligibility criteria), with 
reasons
 N/A
Participants 4a Eligibility criteria for participants  5-6, OSM
4b Settings and locations where the data were 
collected
 5
Interventions 5 The interventions for each group with sufficient 
details to allow replication, including how and 
when they were actually administered
 5-7
Outcomes 6a Completely defined pre-specified primary and 
secondary outcome measures, including how and 
when they were assessed
 7-9
6b Any changes to trial outcomes after the trial 
commenced, with reasons
 N/A
Sample size 7a How sample size was determined  9
7b When applicable, explanation of any interim 
analyses and stopping guidelines
 N/A
Randomisation:
 Sequence 
generation
8a Method used to generate the random allocation 
sequence
 5-6
8b Type of randomisation; details of any restriction 
(such as blocking and block size)
 5-6
 Allocation 
concealment 
mechanism
9 Mechanism used to implement the random 
allocation sequence (such as sequentially 
numbered containers), describing any steps taken
to conceal the sequence until interventions were 
assigned
 5-6
 
Implementation
10 Who generated the random allocation sequence, 
who enrolled participants, and who assigned 
participants to interventions
 5-6
Blinding 11a If done, who was blinded after assignment to 
interventions (for example, participants, care 
providers, those assessing outcomes) and how
 5-6
11b If relevant, description of the similarity of 
interventions
 6
Statistical 
methods
12a Statistical methods used to compare groups for 
primary and secondary outcomes
 9
12b Methods for additional analyses, such as 
subgroup analyses and adjusted analyses
 N/A
Results
Participant flow 
(a diagram is 
strongly 
recommended)
13a For each group, the numbers of participants who 
were randomly assigned, received intended 
treatment, and were analysed for the primary 
outcome
 10
13b For each group, losses and exclusions after 
randomisation, together with reasons
 10, OSM
Recruitment 14a Dates defining the periods of recruitment and 
follow-up
 10/OSM
14b Why the trial ended or was stopped  N/A
Baseline data 15 A table showing baseline demographic and clinical
characteristics for each group
 Table 1
Numbers 
analysed
16 For each group, number of participants 
(denominator) included in each analysis and 
whether the analysis was by original assigned 
groups
 10
Outcomes and 
estimation
17a For each primary and secondary outcome, results 
for each group, and the estimated effect size and 
its precision (such as 95% confidence interval)
 10-12
17b For binary outcomes, presentation of both 
absolute and relative effect sizes is recommended
 N/A
Ancillary 
analyses
18 Results of any other analyses performed, 
including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from 
exploratory
 N/A
Harms 19 All important harms or unintended effects in each 
group (for specific guidance see CONSORT for 
harms)
 10
Discussion
Limitations 20 Trial limitations, addressing sources of potential 
bias, imprecision, and, if relevant, multiplicity of 
analyses
 14-15
Generalisability 21 Generalisability (external validity, applicability) of 
the trial findings
 14
Interpretation 22 Interpretation consistent with results, balancing 
benefits and harms, and considering other 
relevant evidence
 12-15
Other 
information
Registration 23 Registration number and name of trial registry  5
Protocol 24 Where the full trial protocol can be accessed, if 
available
 On request
Funding 25 Sources of funding and other support (such as 
supply of drugs), role of funders
 16
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation
and Elaboration for important clarifications on all the items. If relevant, we also recommend reading
CONSORT  extensions  for  cluster  randomised  trials,  non-inferiority  and  equivalence  trials,  non-
pharmacological  treatments,  herbal  interventions,  and  pragmatic  trials.  Additional  extensions  are
forthcoming:  for  those  and  for  up  to  date  references  relevant  to  this  checklist,  see  www.consort-
statement.org.
 Dietary nitrate supplementation, administered either as a supplement or by consuming nitrate-
rich foods such as beetroot juice, has been associated with improved exercise performance 
 Limited evidence is available on the effects of dietary nitrate supplementation on exercise 
performance in older populations
 This study reported a lack of effect of dietary nitrate on physical performance measured in 
research settings and free-living conditions
